Metabolic
Chipkin Named Founding Editor of the American Journal of Medicine Open | News and media relations office
Research publishing giant Elsevier has announced a new open access companion for the American Journal of Medicine, the founding editor of which is research professor of kinesiology Dr. Stuart Chipkin is.
In its press release, Elsevier states that the American Journal of Medicine Open (“AJM Open”) is “dedicated to the publication of original clinical research in internal medicine that is relevant to community science and practice. All articles are subjected to a strict assessment. It is a companion journal to “The American Journal of Medicine” (“The Green Journal”) and is of a similar size. It publishes original research and reviews in the fields of internal medicine, with an emphasis on articles of immediate clinical interest. “
AJM Open has launched a global call for proposals to be published later in 2021. As an open access journal, its articles are immediately and permanently free for everyone to read, download, copy and distribute.
“My goal is for the AJM Open to be an innovative forum for internal medicine practitioners and their specialties, building bridges in healthcare and building bridges to new and emerging disciplines,” said Chipkin, a practicing endocrinologist. “We are particularly interested in interdisciplinary research, population management and the integration of technology into clinical care. In addition to our publications, we will use social media and related platforms to inform providers about innovations in internal medicine and their specialist areas.”
After Chipkin received his BS from Emory University and his MD from SUNY Downstate, he trained in internal medicine and completed an endocrinology fellowship at the University of Massachusetts Medical School. He joined the faculty at Boston University School of Medicine and developed programs for diabetes care for minorities. His research efforts shifted from cellular glucose transport to clinical studies related to lowering cardiovascular risk in insulin resistant conditions. He also initiated standardized clinical approaches to the care of transgender people at Boston University and became a recognized clinical expert in the field.
Chipkin then joined a large subsidiary of Tufts University, where he became head of endocrinology, diabetes and metabolism. There he developed collaborations with the UMass Amherst faculty and finally joined the UMass Amherst faculty in 2004. He also became a Co-PI for a public health training center that highlighted the role of health care workers at the forefront of color communities. His efforts have continued to emphasize the role of lifestyle changes in insulin resistant conditions, including drug interactions, timing of exercise, nutritional composition, and aging. His work has received funding from the National Institutes of Health, the Health Resources & Services Administration, the American Diabetes Association, the American Heart Association, and the JDRF.
Chipkin was a member of the American Diabetes Association’s Grant Review Panel and Scientific Sessions Committee, and the primary medical advisor on Massachusetts’s initial guidelines for diabetes care. He has been recognized by several organizations for his work in nutrition and public health. He has also maintained a strong clinical interest in areas related to diabetes, lipids, metabolic syndrome, and caring for transgender people.